Loading...
•
Sep 30
Myomo Q3 2025 Earnings Report
Myomo reported third quarter 2025 results with revenue growth, record orders, and solid operational progress despite higher expenses.
Key Takeaways
Myomo achieved strong Q3 2025 performance with revenue up 10% year-over-year to $10.1 million, driven by record MyoPro orders and increased O&P revenues. The company reported a net loss of $3.7 million and an operating loss of $3.5 million, while maintaining a healthy cash balance of $12.6 million. Adjusted EBITDA stood at a loss of $2.7 million, reflecting higher R&D and marketing investments aimed at long-term growth.
Revenue grew 10% year-over-year to $10.1 million, driven by higher MyoPro unit sales.
229 MyoPro orders and authorizations marked the strongest quarter of the year.
Gross margin declined to 63.8% due to higher costs and lower average selling prices.
Cash balance stood at $12.6 million following strategic financing activities.
Myomo
Myomo
Myomo Revenue by Segment
Revenue by Segment
Medicare Part B Revenue
CapyFin.com Forward Guidance
Myomo reaffirmed full-year 2025 revenue guidance of $40–$42 million, implying over 23% annual growth, supported by rising recurring revenues and operational efficiency projects.
Positive Outlook
- Reiterated full-year revenue guidance of $40–$42 million.
- Strong momentum in recurring patient sources via MyoConnect program.
- Manufacturing cost reduction projects expected to boost gross margin by 200 bps in 2026.
- Healthy liquidity with pro forma cash balance of $20.1 million.
- O&P channel expansion driving patient pipeline growth.
Challenges Ahead
- Gross margin declined due to higher material and labor costs.
- Operating expenses increased 26% year-over-year.
- Net loss widened to $3.7 million in the quarter.
- Average selling price declined 5% year-over-year.
- Adjusted EBITDA remained negative at $(2.7) million.